Replacing cells and organs

Aelan researches, discovers, develops, and commercializes biomedical technologies for human health and longevity.

Aspen develops iPSC-derived autologous cell replacement therapies for Parkinson’s disease and other high-unmet-need CNS disorders.

BE Therapeutics develops stem cell-derived replacement brain and spinal cord tissue to reverse CNS damage.

Betalin is developing a stem-cell based micro-pancreas intended to reduce diabetic patients’ dependence on daily insulin.

BlueRock is a clinical-stage cell therapy company investigating replacement of cells damaged or lost to disease.

Cellino develops AI-driven optical bioprocesses for personalized regenerative medicine and patient-specific living medicines.

cellvie develops Therapeutic Mitochondria Transplantation medicines targeting cellular energy metabolism and mitochondria-linked disease processes.

Celularity develops and commercializes placenta-derived biomaterials and allogeneic cryopreserved cell therapies for age-related diseases.

eGenesis advances human-compatible organs for patients with organ failure using genome engineering and transplantation.

FibroBiologics develops fibroblast cell-based therapies and fibroblast-derived treatments for chronic diseases.

Frontier Bio creates tissue-engineered blood vessels and human-based tissue models for vascular grafts and preclinical testing.

Gameto develops cell-engineering technologies for reproductive health, including IVF, egg freezing, ovarian disease, and menopause.

HepaTx develops off-the-shelf stem cell-based regenerative therapies for late-stage liver disease as an alternative to liver transplant.

HexemBio is developing scalable rejuvenated hematopoietic stem cell therapy to reverse aging-related decline in blood stem cells.

Immorta Bio develops longevity therapeutics to reverse aging, eliminate cancer, and rejuvenate organs.

Lineage is a clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies for serious medical conditions.

Leonhardt Ventures develops regenerative medtech innovations focused on bioelectrics and biologics for healthspan, longevity, and healing.

Longeveron develops cell-based regenerative therapies for life-threatening and chronic aging-related conditions.

Pre-clinical biotechnology company developing functional mitochondria as therapeutic agents to treat damaged tissues and organs.

LyGenesis develops cell therapies that use lymph nodes as bioreactors to grow functioning ectopic organs.

MEDIPOST develops stem cell therapeutics, regenerative medicine products, cord blood banking services, CDMO services, and nutritional supplements.

Micregen develops cell-free stem cell-derived secretome therapeutics for degenerative and underdevelopment conditions.

Minovia develops mitochondria-based therapies using mitochondrial transplantation for diseases linked to mitochondrial dysfunction.

Muse Cell Innovations licenses Dezawa MuseCells, MuseSecretomes, and MuseExosomes for regenerative medicine, longevity, aesthetics, orthopedics, and related applications.

NeuroNascent develops oral small-molecule neuron regenerative therapies for chronic neurological disorders including Alzheimer's, Parkinson's and developmental delay.

Regeneration Biomedical develops Wnt-activated autologous stem cell therapies for neurodegenerative diseases.

Rejenevie Therapeutics develops immune restoration treatments targeting age-related diseases using stem cell restoration and parabiosis-inspired cell culture technology.

Sana creates engineered cells as medicines to repair and control genes or replace missing or damaged cells.

Thymmune develops a machine learning-driven thymic cell engineering platform to restore immune function in aging and disease.

Tolerance Bio develops thymus-based therapies to preserve, restore, and manipulate immune tolerance for increased healthspan.

TreeFrog Therapeutics develops iPS-derived regenerative cell therapies using its proprietary C-Stem biomimetic technology platform.

Frontier Bio is a U.S. tissue-engineering startup pursuing two linked product lines: a patient-seeded, bioresorbable vascular graft intended for implantation and remodeling into a living blood vessel, and human tissue models such as lung and blood-brain-barrier/neural systems for preclinical testing. The central promise is plausible in concept and supported by repeated, fairly consistent company and interview claims, some partnership signals, and early preclinical/research-use positioning, but the evidence here is still weak on independent validation: most sources are company-controlled, interview-based, press-style, or investor-marketing materials, and the excerpts do not provide robust methods, sample sizes, peer-reviewed outcomes, or clinical data.

Kind Bio is a U.S. startup pursuing an "integrated organ network" platform: genetically engineered animal systems designed to grow transplantable peripheral organs while lacking higher CNS function and a normal body plan. The core promise is abundant organ supply for transplantation and, longer term, multi-organ replacement for age-related decline. The evidence is still early and mostly self-described or patent-based; there is no peer-reviewed demonstration here of functional human-ready organs, clinical efficacy, or scalable manufacturing.

BioDome-R is an early-stage academic proof-of-concept for a small wearable regenerative bioreactor that creates a sealed local wound microenvironment and delivers short-term pro-regenerative cues in small-animal models. The strongest support in the provided evidence is not clinical efficacy but plausibility: related literature supports the relevance of mechanochemical control, wearable hydrogel patches, and flexible wound bioelectronics, while the project-specific evidence shows a concrete preclinical plan, explicit safety endpoints, and a narrow immediate goal of testing feasibility, tolerability, and biological response rather than claiming regeneration or translation.